Published in AAPS PharmSciTech on September 15, 2010
Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung (2012) 0.92
Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems. J Drug Deliv (2016) 0.75
Physical properties of the fluid lipid-bilayer component of cell membranes: a perspective. Q Rev Biophys (1991) 5.96
Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem (1980) 5.45
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest (1992) 2.33
Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother (1991) 1.88
Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst (1995) 1.66
Terbutaline inhalations by the Turbuhaler as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease. Respir Med (1994) 1.46
Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv (1995) 1.40
Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care (2004) 1.38
Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem (2001) 1.30
Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res (1995) 1.28
Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care (2005) 1.19
Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm (1998) 1.18
Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids (1986) 1.18
Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm (2004) 1.10
The effects of lyophilization on the stability of liposomes containing 5-FU. Int J Pharm (2005) 1.09
Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech (2001) 1.05
Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis (1993) 1.05
Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Appl Physiol (1985) (1993) 1.02
Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization. Int J Pharm (2001) 0.97
Inhaled insulin. Adv Drug Deliv Rev (1999) 0.97
Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res (1991) 0.95
The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm Res (1989) 0.95
Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax (1995) 0.95
Development of dry powder inhalers. Recent Pat Drug Deliv Formul (2007) 0.93
The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res (2006) 0.92
Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech (2004) 0.92
Nebulization of liposomes. I. Effects of lipid composition. Pharm Res (1990) 0.92
Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech (2005) 0.91
Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. J Control Release (2003) 0.91
Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther (2004) 0.90
Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J Pharmacol Exp Ther (1999) 0.90
Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opin Drug Deliv (2009) 0.89
Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm Res (1991) 0.87
Stability of lyophilized human growth hormone. Int J Pharm (2008) 0.86
The effect of aging on the physical stability of liposome dispersions. Chem Phys Lipids (1992) 0.86
Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm Res (1992) 0.86
Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci (2003) 0.85
Determination of the glass properties of D-mannitol using sorbitol as an impurity. J Pharm Sci (1998) 0.85
Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul (2009) 0.85
Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. Am Rev Respir Dis (1990) 0.84
Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat. J Natl Cancer Inst (1979) 0.84
Hydrolysis of partially saturated egg phosphatidylcholine in aqueous liposome dispersions and the effect of cholesterol incorporation on hydrolysis kinetics. J Pharm Pharmacol (1993) 0.84
Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother (1988) 0.83
A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J Pharm Sci (2002) 0.81
Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Chest (1996) 0.81
Tryptase mediates hyperresponsiveness in isolated guinea pig bronchi. Life Sci (1998) 0.80
Alkaline hydrolysis of phospholipids in model membranes and the dependence on their state of aggregation. Biochemistry (1981) 0.79
The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. Transplantation (1994) 0.79
Delivery of liposomes in dry powder form: aerodynamic dispersion properties. Eur J Pharm Sci (2003) 0.78
Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance. Pharmazie (2004) 0.78
The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. Scand J Clin Lab Invest (1990) 0.77
Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci (2009) 0.76
The effect of jet-milling on lyophilized liposomes. Pharm Res (1998) 0.76
Steroid resistance in asthma. Molecular mechanisms. Am J Respir Crit Care Med (1996) 0.76
Secretory leukocyte protease inhibitor, but not alpha-1 protease inhibitor, blocks tryptase-induced bronchoconstriction. Pulm Pharmacol Ther (2001) 0.76
Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine. Pharm Res (1989) 0.76
Lyophilized liposomes: a new method for long-term vesicular storage. J Microencapsul (1989) 0.76
Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther (2011) 2.75
Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med (2011) 2.37
Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med (2014) 2.14
Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med (2012) 1.93
Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest (2004) 1.88
Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med (2009) 1.86
TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol (2005) 1.67
Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med (2005) 1.65
Endotoxin up-regulates interleukin-18: potential role for gram-negative colonization in sarcoidosis. Am J Respir Crit Care Med (2005) 1.57
Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol (2004) 1.53
Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem (2002) 1.52
Alpha-1 antitrypsin deficiency. Respir Med (2010) 1.51
Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell (2011) 1.48
miR-199a-5p silencing regulates the unfolded protein response in chronic obstructive pulmonary disease and α1-antitrypsin deficiency. Am J Respir Crit Care Med (2014) 1.46
miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med (2014) 1.45
α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses. Am J Respir Crit Care Med (2014) 1.45
Adult-onset nemaline myopathy presenting as respiratory failure. Respir Care (2008) 1.40
Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett (2003) 1.38
α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest (2010) 1.38
miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol (2010) 1.38
Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res (2007) 1.31
Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis (2004) 1.25
MicroRNAs in inflammatory lung disease--master regulators or target practice? Respir Res (2010) 1.24
Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol (2003) 1.24
LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol (2009) 1.22
Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem (2008) 1.20
Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest (2013) 1.20
Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun (2004) 1.20
Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br J Pharmacol (2009) 1.18
Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res (2006) 1.18
Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med (2005) 1.18
Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol (2007) 1.17
Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis. Chest (2010) 1.09
Toll-like receptor expression and function in airway epithelial cells. Arch Immunol Ther Exp (Warsz) (2005) 1.09
Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv (2010) 1.08
17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med (2010) 1.08
Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol (2009) 1.07
Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm (2008) 1.07
Cytosolic pH and the inflammatory microenvironment modulate cell death in human neutrophils after phagocytosis. Blood (2002) 1.06
Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J Immunol (2010) 1.05
Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem (2008) 1.03
Selenoprotein S/SEPS1 modifies endoplasmic reticulum stress in Z variant alpha1-antitrypsin deficiency. J Biol Chem (2009) 1.01
Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets (2008) 1.00
Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem (2006) 1.00
A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm (2008) 0.99
The CF-ABLE score: a novel clinical prediction rule for prognosis in patients with cystic fibrosis. Chest (2013) 0.99
Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway. J Biol Chem (2010) 0.98
The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med (2014) 0.97
Tauroursodeoxycholic acid inhibits apoptosis induced by Z alpha-1 antitrypsin via inhibition of Bad. Hepatology (2007) 0.95
Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia? Respirology (2009) 0.94
The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir Res (2011) 0.93
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. ScientificWorldJournal (2012) 0.92
Isolation and identification of cell-specific microRNAs targeting a messenger RNA using a biotinylated anti-sense oligonucleotide capture affinity technique. Nucleic Acids Res (2013) 0.92
The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch Immunol Ther Exp (Warsz) (2011) 0.92
Aspergillus-associated airway disease, inflammation, and the innate immune response. Biomed Res Int (2013) 0.91
Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J Inflamm Res (2013) 0.91
IL-8 dictates glycosaminoglycan binding and stability of IL-18 in cystic fibrosis. J Immunol (2009) 0.91
SLPI and inflammatory lung disease in females. Biochem Soc Trans (2011) 0.91
Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch Immunol Ther Exp (Warsz) (2012) 0.91
Regulation of cystic fibrosis transmembrane conductance regulator by microRNA-145, -223, and -494 is altered in ΔF508 cystic fibrosis airway epithelium. J Immunol (2013) 0.90
The effect of Aspergillus fumigatus infection on vitamin D receptor expression in cystic fibrosis. Am J Respir Crit Care Med (2012) 0.89
Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J Immunol (2011) 0.89
Chitosan for gene delivery and orthopedic tissue engineering applications. Molecules (2013) 0.88
Inhibition of Toll-like receptor 2-mediated interleukin-8 production in Cystic Fibrosis airway epithelial cells via the alpha7-nicotinic acetylcholine receptor. Mediators Inflamm (2010) 0.88
Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases. Biol Chem (2010) 0.88
The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res (2014) 0.88
Secretory leucocyte protease inhibitor inhibits interferon-gamma-induced cathepsin S expression. J Biol Chem (2007) 0.86
Therapeutic modulation of miRNA for the treatment of proinflammatory lung diseases. Expert Rev Anti Infect Ther (2012) 0.86
Circulating polymers in α1-antitrypsin deficiency. Eur Respir J (2014) 0.85
Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul (2009) 0.85
Toll-like receptors as therapeutic targets in cystic fibrosis. Expert Opin Ther Targets (2008) 0.85
High levels of ephrinB2 over-expression increases the osteogenic differentiation of human mesenchymal stem cells and promotes enhanced cell mediated mineralisation in a polyethyleneimine-ephrinB2 gene-activated matrix. J Control Release (2012) 0.85
The development of non-viral gene-activated matrices for bone regeneration using polyethyleneimine (PEI) and collagen-based scaffolds. J Control Release (2011) 0.84
Combinatorial gene therapy accelerates bone regeneration: non-viral dual delivery of VEGF and BMP2 in a collagen-nanohydroxyapatite scaffold. Adv Healthc Mater (2014) 0.84
Protein misfolding and obstructive lung disease. Proc Am Thorac Soc (2010) 0.84
Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J Gastrointest Pharmacol Ther (2010) 0.83
The involvement of glycosaminoglycans in airway disease associated with cystic fibrosis. ScientificWorldJournal (2011) 0.83
Increased outer arm and core fucose residues on the N-glycans of mutated alpha-1 antitrypsin protein from alpha-1 antitrypsin deficient individuals. J Proteome Res (2013) 0.82
Increased expression of interleukin-9, interleukin-9 receptor, and the calcium-activated chloride channel hCLCA1 in the upper airways of patients with cystic fibrosis. Laryngoscope (2003) 0.82
The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency. Expert Rev Respir Med (2011) 0.82
The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation. AAPS PharmSciTech (2011) 0.82
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. Biologics (2009) 0.82
Quantification and evaluation of the role of antielastin autoantibodies in the emphysematous lung. Pulm Med (2011) 0.82
Immunoevasive Aspergillus virulence factors. Mycopathologia (2014) 0.81
Neutrophil elastase up-regulates human beta-defensin-2 expression in human bronchial epithelial cells. FEBS Lett (2003) 0.81
In vitro activities of synthetic host defense propeptides processed by neutrophil elastase against cystic fibrosis pathogens. Antimicrob Agents Chemother (2011) 0.81
A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis. J Cyst Fibros (2011) 0.81
Effect of pro-inflammatory stimuli on mucin expression and inhibition by secretory leucoprotease inhibitor. Cell Microbiol (2006) 0.80
Immune, inflammatory and infectious consequences of estrogen in women with cystic fibrosis. Expert Rev Respir Med (2012) 0.80
Ivacaftor: from bench to bedside... and back again. Am J Respir Crit Care Med (2014) 0.80
Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung. J Immunol (2014) 0.80
Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5-triphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease. Biomed Res Int (2013) 0.79
Non-viral gene-activated matrices: next generation constructs for bone repair. Organogenesis (2013) 0.79
Therapeutic aerosol bioengineering of siRNA for the treatment of inflammatory lung disease by TNFα gene silencing in macrophages. Mol Pharm (2014) 0.79
miR-CATCH: microRNA capture affinity technology. Methods Mol Biol (2015) 0.79
Viral inhibition of IL-1- and neutrophil elastase-induced inflammatory responses in bronchial epithelial cells. J Immunol (2005) 0.79